The real-world weight loss effectiveness of GLP-1RAs have not been well described. We conducted a cohort study using EHR data from an integrated healthcare system based in PA. Non-pregnant adults first dispensed a GLP-1RA between 20 and 2018 were eligible. We excluded those without:

  • 1) at least 72 weeks of continuous enrollment after the first dispense date,

  • 2) at least 1 year of baseline enrollment data, and

  • 3) at least one valid weight measurement within the 8 wks before the dispense date and at least one weight measure during follow-up.

We used descriptive statistics to report percent change in body weight from baseline in each 8 wk follow-up interval ending in +72 wks. We used linear mixed models with a person-level random intercept controlling for variables associated with missing weight data to estimate percent body weight change during follow-up. Our cohort included 2,398 patients (mean[SD] age 48.4[10.3], 53% female) , with a BMI[SD] of 37[7.5] and a mean baseline weight of 238[54] lbs. In the final 8 wk interval of follow-up (64-72 wks) , the modeled mean percent weight change was -2.5% (95% CI: -2.8 to -2.1) . An estimated 29.9% (95% CI: 27.2 to 32.6) of patients lost at least 5% body weight at this time. In this real-world study using data from ∼2,400 patients with overweight or obese and type 2 diabetes, starting a GLP-1RA was associated with a modest amount of weight loss through 72 weeks.

Disclosure

J.Luo: None. I.Shu: None. M.T.Korytkowski: None. D.A.Rometo: Advisory Panel; Nestlé Health Science. J.Arnold: None. G.E.White: None.

Funding

NIDDK (K23ADK120956)

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.